EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ.

OBJECTIVES On behalf of the European Association of Urology (EAU), guidelines for the diagnosis, therapy and follow-up of patients with urothelial carcinoma in situ (CIS) have been established. METHOD The recommendations in these guidelines are based on a recent comprehensive overview and meta-analysis in which two panel members have been involved (RS and AVDM). A systematic literature search was conducted using Medline, the US Physicians' Data Query (PDQ), the Cochrane Central Register of Controlled Trials, and reference lists in trial publications and review articles. RESULTS Recommendations are provided for the diagnosis, conservative and radical surgical treatment, and follow-up of patients with CIS. Levels of evidence are influenced by the lack of large randomized trials in the treatment of CIS.

[1]  H. Zincke,et al.  Carcinoma in Situ of the Bladder , 1980, Cancer.

[2]  R. Bahnson,et al.  Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. , 1997, Urology.

[3]  Georg Bartsch,et al.  Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. , 2003, Urology.

[4]  P. Navarra,et al.  Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. , 2003, The Journal of urology.

[5]  C. Roehrborn,et al.  Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.

[6]  M. Sarosdy.  A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract. , 1997, European urology.

[7]  M. Melekos,et al.  Intravesical 4′‐epi‐doxorubicin(epirubicin) versus bacillus calmette—guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer , 1993, Cancer.

[8]  J. Witjes,et al.  A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. , 1995, The Journal of urology.

[9]  R. Hall.  Clinical Management of Bladder Cancer , 1999 .

[10]  K. Ohya,et al.  Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette‐Guerin therapy for carcinoma in situ of the bladder , 2001, International journal of urology : official journal of the Japanese Urological Association.

[11]  J. Witjes.  Bladder carcinoma in situ in 2003: state of the art. , 2004, European urology.

[12]  D. L. Lamm,et al.  Carcinoma in situ. , 1992, The Urologic clinics of North America.

[13]  J. Witjes,et al.  Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. , 2005, The Journal of urology.

[14]  A. Lopez‐Beltran,et al.  Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. , 2004, European urology.

[15]  P. Scardino,et al.  A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. , 1991, The New England journal of medicine.

[16]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[17]  R. Bahnson,et al.  Initial report on intraves1cal administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder , 1997 .

[18]  M. Sarosdy,et al.  The significance of central pathology review in clinical studies of transitional cell carcinoma in situ. , 1997, The Journal of urology.

[19]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[20]  R. Babayan,et al.  Carcinoma in situ of the bladder , 1983, World Journal of Urology.

[21]  F M Debruyne,et al.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. , 1992, The Journal of urology.

[22]  Gerhard Jakse,et al.  Guidelines on bladder cancer. , 2002, European urology.

[23]  François Guillemin,et al.  Fluorescence detection of bladder cancer: a review. , 2002, European urology.

[24]  G. Steinberg,et al.  The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. , 2001, The Journal of urology.

[25]  E. Solsona,et al.  Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management. , 1997, Urology.

[26]  P. Russo,et al.  Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. O'Donnell,et al.  Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures , 2004, Current opinion in urology.

[28]  G. Jakse.  BCG for carcinoma in situ. , 1992, European urology.

[29]  P. Carroll,et al.  Bropirimine immunotherapy of upper urinary tract carcinoma in situ. , 1996, Urology.

[30]  D. Lamm,et al.  Updated concepts and treatment of carcinoma in situ. , 1998, Urologic oncology.

[31]  N. Nonomura,et al.  Bacillus Calmette–Guérin Perfusion Therapy for the Treatment of Transitional Cell Carcinoma in situ of the Upper Urinary Tract , 2000, European Urology.

[32]  M. O'Donnell,et al.  Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. , 2004, The Journal of urology.

[33]  Jörg Schmidbauer,et al.  Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. , 2004, The Journal of urology.

[34]  W. Catalona,et al.  Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. , 1990, The Journal of urology.

[35]  P. Malmström,et al.  Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. , 2003, European urology.

[36]  P. Schellhammer,et al.  Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. , 1995, Urologic oncology.

[37]  J. Witjes,et al.  High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. , 2005, Urology.

[38]  S. Loening,et al.  1497: Use of Propsa within Artificial Neural Networks to Improve Prostate Cancer Specificity , 2005 .

[39]  R. Sylvester,et al.  Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. , 2003, European urology.

[40]  Carcinoma in situ. , 1979, Human pathology.

[41]  Marije Deutekom,et al.  Tumor markers in the diagnosis of primary bladder cancer. A systematic review. , 2003, The Journal of urology.

[42]  U. Nseyo,et al.  Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. , 1998, Journal of clinical laser medicine & surgery.

[43]  K. Ogan,et al.  Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium. , 2003, Journal of endourology.

[44]  P. Carroll,et al.  Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. , 1998, Urology.

[45]  S. Fukushima,et al.  CURRENT METHODS OF ASSESSING AND TREATING CARCINOMA IN SITU OF THE BLADDER WITH OR WITHOUT INVOLVEMENT OF THE PROSTATIC URETHRA , 1995, International journal of urology.

[46]  J. Hannigan,et al.  Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Patard,et al.  Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. , 2001, Urology.

[48]  R. Sylvester,et al.  Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. , 2001, The Journal of urology.

[49]  R. Sylvester,et al.  Intravesical BCG in Patients with Carcinoma in situ of the Urinary Bladder: Long–Term Results of EORTC GU Group Phase II Protocol 30861 , 2001, European Urology.

[50]  B. Norlén,et al.  5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. , 1999, The Journal of urology.

[51]  A. Lembo,et al.  Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. , 2000, The Journal of urology.

[52]  R. Glashan.  A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. , 1990, The Journal of urology.

[53]  L. Martínez-Piñeiro,et al.  Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. , 1990, The Journal of urology.

[54]  J. Witjes,et al.  Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. , 1998, The Journal of urology.

[55]  P. Schellhammer,et al.  Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. , 1996, Urology.

[56]  G. Morgia,et al.  Use of BCG in Immunotherapy of Superficial Bladder Cancer: Multicentric Investigation on Safety and Compliance , 2003 .

[57]  D. Mehraban,et al.  Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906). , 2005, The Journal of urology.

[58]  W. Whitmore,et al.  Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management. , 1987, The Journal of urology.

[59]  U. Studer,et al.  Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. , 2002, The Journal of urology.

[60]  A. Böhle,et al.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. , 2003, The Journal of urology.

[61]  D. Schwartz.  Union Internationale Contre le Cancer (UICC) , 2005 .

[62]  D. Lamm,et al.  INTRAVESICAL CHEMOTHERAPY AND IMMUNOTHERAPY: HOW DO WE ASSESS THEIR EFFECTIVENESS AND WHAT ARE THEIR LIMITATIONS AND USES? , 1995, International journal of urology : official journal of the Japanese Urological Association.

[63]  K. Jauhiainen,et al.  Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. , 1995, The Journal of urology.

[64]  D. Ackermann,et al.  Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder. , 1995, British journal of urology.

[65]  Richard Sylvester,et al.  Long-Term Follow-Up of an EORTC Randomized Prospective Trial Comparing Intravesical Bacille Calmette-Guerin-RIVM and Mitomycin C in Superficial Bladder Cancer , 1999 .

[66]  R. Bahnson,et al.  EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER , 2000 .

[67]  U. Nseyo,et al.  Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. , 1998, The Journal of urology.

[68]  Herbert Stepp,et al.  Role of 5‐aminolevulinic acid in the detection of urothelial premalignant lesions , 2002, Cancer.

[69]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .